Abbvie Reports the US FDA Approval for Emblaveo to Treat Complicated Intra-Abdominal Infections (cIAI)
Shots:
- The US FDA has approved Emblaveo (IV) + metronidazole for pts (≥18 yrs) with few or no therapy options for cIAI caused by susceptible gram -ve bacteria, incl. E. coli, K. pneumoniae, K. oxytoca, ECC, C. freundii complex, & S. marcescens; commercially available in Q3’25
- Approval was based on prior aztreonam’s efficacy & safety data for cIAI, plus P-III (REVISIT) trial, assessing Emblaveo ± metronidazole vs meropenem ± colistin in 422 pts with cIAI or nosocomial pneumonia (HAP/VAP); data published in The Lancet
- Emblaveo combines aztreonam (monobactam) & avibactam (β-lactamase inhibitor) that protects aztreonam from serine β-lactamase (SBL) hydrolysis, while restoring its activity against MBL- & SBL-producing bacteria
Ref: Abbvie | Image: Abbvie
Related News:- Abbvie Partners with Neomorph to Develop Novel Molecular Glue Degraders for Oncology and Immunology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
